23.11.2010 • NewsCollaborationcooperationEvotec

Evotec, Merck KGaA Collaborate on Neurological Disease Target

Evotec has signed an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.

The cooperation will take place within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research.

Company

Evotec

Schnackenburgallee 114
22525 Hamburg
Germany

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.